Press Releases All News 2019 2018 2017 2016 2015 2014 Relmada Therapeutics Announces $6.9 Million Private Placement October 5, 2017 Relmada Therapeutics Appoints Dr. Maurizio Fava as Chair of the Dextromethadone Scientific Advisory Board for its Depression Program June 28, 2017 Dr. Ottavio Vitolo Appointed Executive Clinical Advisor at Relmada Therapeutics June 21, 2017 Charles J. Casamento Appointed Chairman of Relmada Therapeutics Board of Directors June 15, 2017 Relmada Therapeutics Announces Settlement of Legal Action with Laidlaw & Company May 18, 2017 Relmada Announces FDA Fast Track Designation for d-Methadone for Adjunctive Treatment of Major Depressive Disorder April 13, 2017 Relmada Therapeutics to Participate in the 2nd Annual Disruptive Growth & Healthcare Conference February 15, 2017 Relmada Therapeutics to Participate in BIO CEO and Investor Conference February 13, 2017 Relmada Announces FDA Acceptance of IND and Authorization to Commence Phase 2a Clinical Trial for d-Methadone January 25, 2017 Relmada Therapeutics to Provide an Update on the Development Plan for LevoCap ER January 24, 2017 « Previous 1 2 3 4 5 6 7 8 9 10 ...12 Next »
Relmada Therapeutics Appoints Dr. Maurizio Fava as Chair of the Dextromethadone Scientific Advisory Board for its Depression Program June 28, 2017
Relmada Announces FDA Fast Track Designation for d-Methadone for Adjunctive Treatment of Major Depressive Disorder April 13, 2017
Relmada Therapeutics to Participate in the 2nd Annual Disruptive Growth & Healthcare Conference February 15, 2017
Relmada Announces FDA Acceptance of IND and Authorization to Commence Phase 2a Clinical Trial for d-Methadone January 25, 2017